Novartis raised its medium-term sales guidance to 6% annual growth up to 2028, driven by strong momentum of launched drugs and the prospect of upcoming launches.

RTÉ

Ireland

Novartis raises sales guidance up to 2028

Media Bias/Fact Check

Government of Ireland

CEO Vas Narasimhan said the Novartis pipeline has "significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029."

Ad Fontes Media

All Sides

Fortune

Chatchaval Jiaravanon

New York

United States

Swiss pharma giant Novartis says 30 pipeline drugs with 'significant potential' will drive long-term growth

Novartis AG raised its medium-term sales target, citing upbeat expectations for new cancer and immunological disease medicines, as well as treatments for neurological and cardiovascular conditions.Revenue will grow 6% a year through 2029, the Basel, Switzerland-based drugmaker said on Thursday, an upgrade from its previous guidance of 5%. Novartis shares rose slightly in early trading Thursday. The company’s stock has risen 7.2% this year throug…

NDTV Profit

Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs

Novartis reworked its medium-term roadmap on Thursday. It forecasts a growth of 6% per year over the period 2023-2028, and of one percentage point compared to the last update. Projections to 2029 lead to a return of this threshold to 5%.

Novartis a retravaillé sa feuille de route à moyen-terme jeudi. Il prévoit une croissance de 6% par an sur la période 2023-2028, et d'un point de pourcentage par rapport à la dernière mise à jour. Les projections à 2029 induisent un retour de cette balise à 5%.

Novartis réarrange ses jalons de croissance à moyen-terme

pme.ch

Novartis rearranges its medium-term growth milestones

FRANKFURT – Novartis (NYSE: NVS) raised its medium-term sales guidance on Thursday to 6% annual growth through 2028, driven by the momentum of launched drugs and the prospect of upcoming launches. The Swiss drugmaker was previously targeting mid-term currency-adjusted sales growth of at least 5% from 2023 to 2028. However, the company said it was still expecting 5% sales growth per year during the 2024-2029 period, given its strong performance i…

abbonews.com

Novartis Raises Sales Guidance Until 2028

Ad hoc announcement pursuant to Art. 53 LR 
Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029 Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ peak sales potential and 15+ near-term submission-enabling readouts  30+ high-value medicines in the pipeline expected to support continued mid-single digit sales growth beyond 2029  Basel, November 21, 2024 – Today Novartis announced an upgrade to i…

Novartis raises sales guidance up to 2028

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics